Prazosin Recall 2025: Distributor Action Requirements

FDA Recalls Prazosin Hydrochloride Capsules: What Wholesale Distributors Need to Know

Torrent Pharma initiated a voluntary nationwide recall of prazosin hydrochloride capsules on January 8, 2025, covering 1 mg, 2 mg, and 5 mg strengths. The recall affects multiple lot numbers distributed between March 2023 and November 2024, requiring wholesale distributors to immediately verify inventory and execute customer notification protocols under 21 CFR Part 7.

Regulatory Context

The FDA classifies this as a Class II recall under 21 CFR 7.3(m)(2), indicating a situation where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences. The probability of serious adverse health consequences is remote.

Wholesale drug distributors are subject to specific recall obligations under 21 CFR 205.50(g), which requires written notification to direct customers within three business days of receiving a recall notice from a manufacturer. The Drug Supply Chain Security Act (DSCSA) Section 582(c)(4) further requires distributors to maintain systems for promptly responding to notifications regarding illegitimate product in the pharmaceutical distribution supply chain.

Affected Lots and Distribution Timeline

The recall covers the following prazosin hydrochloride capsule strengths and lot numbers:

1 mg capsules:

• Lot AN3366, expiration 03/2026
• Lot AN3367, expiration 03/2026
• Lot AP4011, expiration 06/2026

2 mg capsules:

• Lot AN3368, expiration 03/2026
• Lot AP4012, expiration 06/2026

5 mg capsules:

• Lot AN3369, expiration 03/2026
• Lot AP4013, expiration 06/2026

Distribution occurred between March 2023 and November 2024 across wholesale and retail channels. Torrent Pharma has not disclosed the recall reason in publicly available FDA Enforcement Reports as of January 15, 2025. The FDA has not issued a separate Drug Safety Communication regarding this recall.

Distributor Action Requirements

Wholesale drug distributors holding inventory of the affected lot numbers must:

1. Quarantine inventory — Segregate all affected lots from saleable stock immediately upon receiving manufacturer notification.

1. Verify lot numbers — Cross-reference the seven affected lot numbers against current inventory records. Under DSCSA transaction history requirements at Section 582(b)(1), distributors should have lot-level tracking for all transactions occurring after November 27, 2023.

1. Notify direct customers — Identify all downstream trading partners who received the affected lots and provide written notification within three business days, per 21 CFR 205.50(g). Notification must include specific lot numbers, expiration dates, and return instructions.

1. Document compliance — Maintain records of quarantine actions, customer notifications, and product returns. The FDA expects distributors to produce these records during inspections under 21 CFR Part 205 Subpart D.

1. Arrange product return — Coordinate with Torrent Pharma for return logistics. The manufacturer's recall notice should specify return procedures and any credit or replacement arrangements.

DSCSA Transaction Data Implications

Distributors who transacted the affected lots after November 27, 2023 (the DSCSA enhanced drug distribution security deadline for lot-level data) should have transaction information, transaction history, and transaction statements in EPCIS 1.2 format. This data enables faster identification of affected trading partners compared to legacy paper-based systems.

Distributors using verification router services (VRS) can leverage ATP (Authorized Trading Partner) verification to confirm the authenticity of their upstream and downstream partners during the recall process, though VRS is not directly involved in recall execution.

Reporting to State Boards of Pharmacy

Some states require wholesale drug distributors to report recalls to the state board of pharmacy within a specified timeframe. Requirements vary by jurisdiction:

• California (Business and Professions Code Section 4127.1): Wholesalers must report recalls within 48 hours if the product was distributed in California.
• Florida (Rule 64F-12.019): Notification required within three business days of receiving a recall notice.
• Texas (22 TAC §291.18): Distributors must maintain recall procedures and notify the Texas State Board of Pharmacy upon request.

Distributors should consult their state-specific wholesale drug distributor license requirements to confirm recall reporting obligations.

What ColdChainCheck Data Shows

ColdChainCheck tracks 73 entities with FDA recalls on record out of 1,275 wholesale drug distributors, 3PLs, and cold chain providers in the directory. This prazosin recall adds to the enforcement signal landscape that QA managers use when qualifying and monitoring trading partners.

The average compliance score across all tracked entities is 51/100, placing the industry median in the "Fair" tier. Recall history represents one of six compliance dimensions in the ColdChainCheck scoring model, weighted at 10 points. Entities with active recalls or multiple enforcement actions receive reduced scores in this category.

Of the 1,234 entities with verified FDA registration in the directory, only 63 hold NABP accreditation (formerly VAWD). NABP-accredited distributors undergo additional operational and quality system audits beyond state licensure requirements, which may correlate with stronger recall response procedures — though accreditation does not eliminate recall risk.

Immediate Actions for Compliance Officers

• Check your trading partners: Use the ColdChainCheck directory to verify whether distributors in your supply chain have prior recall enforcement actions. Search by entity name or state to access compliance scores and recall history.

• Verify lot-level tracking: If your organization received prazosin hydrochloride from a wholesale distributor after November 27, 2023, confirm the distributor provided EPCIS transaction data with lot numbers. This is a DSCSA compliance verification point — distributors who cannot provide lot-level data for transactions after the enhanced deadline are non-compliant.

• Document due diligence: Add this recall to your trading partner monitoring log. If a distributor notified you of the affected lots within three business days per 21 CFR 205.50(g), document the notification date. Late notification is a compliance red flag.

• Review state-specific obligations: Cross-reference your state's wholesale drug distributor regulations to confirm whether your organization (if you hold a distributor license) must report the recall to the state board of pharmacy. Not all states require proactive reporting, but several do.

ColdChainCheck tracks FDA enforcement reports and state board of pharmacy actions as compliance signals. For related guidance on DSCSA transaction requirements and recall procedures, see the compliance guides section. Recall data is sourced from FDA Enforcement Reports and updated as new enforcement actions are published.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Wholesale drug distributors should consult legal counsel and verify all recall obligations with the relevant regulatory authorities and state boards of pharmacy.